Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Progenics Pharmaceuticals (PGNX)

Progenics Pharmaceuticals (PGNX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 311,119
  • Shares Outstanding, K 86,422
  • Annual Sales, $ 15,620 K
  • Annual Income, $ -67,660 K
  • 60-Month Beta 2.76
  • Price/Sales 19.92
  • Price/Cash Flow N/A
  • Price/Book 4.19

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate -0.27
  • Number of Estimates 1
  • High Estimate -0.27
  • Low Estimate -0.27
  • Prior Year -0.09
  • Growth Rate Est. (year over year) -200.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.54 +4.52%
on 08/15/19
5.56 -33.45%
on 07/31/19
-1.60 (-30.19%)
since 07/16/19
3-Month
3.54 +4.52%
on 08/15/19
6.31 -41.36%
on 07/01/19
-1.14 (-23.55%)
since 05/16/19
52-Week
3.54 +4.52%
on 08/15/19
8.11 -54.38%
on 08/27/18
-4.19 (-53.11%)
since 08/16/18

Most Recent Stories

More News
Velan Highlights Progenics Pharmaceuticals' Continued Mismanagement Following Q2 2019 Earnings Results

Velan Capital, L.P. (together with the other members of its group, "Velan" or "we"), one of the largest stockholders of Progenics Pharmaceuticals, Inc. ("Progenics" or the "Company")(NASDAQ: PGNX), comprised...

PGNX : 3.70 (+2.78%)
Progenics (PGNX) Reports Q2 Loss, Tops Revenue Estimates

Progenics (PGNX) delivered earnings and revenue surprises of -9.52% and 55.72%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

PGNX : 3.70 (+2.78%)
Progenics: 2Q Earnings Snapshot

NEW YORK (AP) _ Progenics Pharmaceuticals Inc. (PGNX) on Friday reported a loss of $19.7 million in its second quarter.

PGNX : 3.70 (+2.78%)
Progenics Pharmaceuticals Announces Second Quarter 2019 Financial Results and Business Update

-- Enrollment Completed Ahead of Schedule in Phase 3 CONDOR Trial of PyL(F-DCFPyL); Topline Data Expected by Year End 2019

PGNX : 3.70 (+2.78%)
Progenics Pharmaceuticals Announces Additional Governance Enhancements

Board Accepts Resignations of Directors Peter J. Crowley and Michael D. Kishbauch,

PGNX : 3.70 (+2.78%)
CMS Grants New Technology Add-On Payment for Inpatient Use of AZEDRA(R) (iobenguane I 131)

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced that the Centers...

PGNX : 3.70 (+2.78%)
Progenics Pharmaceuticals Completes Enrollment in Pivotal Phase 3 CONDOR Study of PyL for the Detection of Prostate Cancer

Top-line Data Now Expected by Year End

PGNX : 3.70 (+2.78%)
Progenics Pharmaceuticals Sets Second Quarter 2019 Financial Results and Business Update Call for August 9

Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced that it will host...

PGNX : 3.70 (+2.78%)
Progenics Pharmaceuticals Announces Collaboration with Veterans Affairs on the AI Research Program for Medical Image Analysis

Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and imaging technology for targeting and treating cancer, announced their collaboration with the VA Greater...

PGNX : 3.70 (+2.78%)
Velan Announces Progenics Pharmaceuticals Stockholders Support its Campaign for Change at Progenics' 2019 Annual Meeting

Velan Capital, L.P. (together with the other members of its group, "Velan" or "we"), one of the largest stockholders of Progenics Pharmaceuticals, Inc. ("Progenics" or the "Company")(NASDAQ: PGNX), comprised...

PGNX : 3.70 (+2.78%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Average.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade PGNX with:

Business Summary

Progenics Pharmaceuticals, Inc. is developing innovative medicines for oncology, with a pipeline that includes several product candidates in later-stage clinical development. Progenics' first-in-class PSMA-targeted technology platform for prostate cancer includes an antibody drug conjugate therapeutic...

See More

Key Turning Points

2nd Resistance Point 3.89
1st Resistance Point 3.79
Last Price 3.70
1st Support Level 3.62
2nd Support Level 3.55

See More

52-Week High 8.11
Fibonacci 61.8% 6.36
Fibonacci 50% 5.82
Fibonacci 38.2% 5.29
Last Price 3.70
52-Week Low 3.54

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar